FDA Payor Communications Guidance 2026: What Medical Device Manufacturers Need to Know

FDA Payor Communications Guidance 2026: What Medical Device Manufacturers Need to Know

The US FDA's June 3, 2026 draft guidance on manufacturer communications with payors marks a significant policy shift for the medical device industry. This episode breaks down how the guidance extends the safe harbor for sharing Healthcare Economic Information (HCEI) to medical devices and incorporates the Pre-Approval Information Exchange (PIE) Act. We discuss the practical implications for market access, what constitutes 'competent and reliable scientific evidence,' and the steps regulatory and commercial teams should take now to align with the FDA's new framework for communicating with payors about both approved and unapproved products. Key Questions: - What is the FDA's new draft guidance on payor communications issued on June 3, 2026? - How does this guidance extend the HCEI safe harbor to medical devices? - What does the incorporation of the Pre-Approval Information Exchange (PIE) Act mean for manufacturers? - Who is considered a 'payor' under this new framework? - What kind of information can be shared about unapproved devices or unapproved uses? - What constitutes 'competent and reliable scientific evidence' for HCEI claims? - How should medical device companies update their communication strategies with payors? - What practical steps should regulatory and commercial teams take now? Sources: - https://www.kslaw.com/news-and-insights/fda-issues-new-draft-guidance-addressing-communications-with-payors - https://www.arnoldporter.com/en/perspectives/advisories/2026/06/fda-proposes-revised-payor-communications How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex landscapes like the US FDA's evolving requirements. Our experts develop efficient regulatory strategies for market access, leveraging deep local knowledge to ensure your payor communications and technical dossiers meet all standards. We use advanced AI to compile and manage submissions, accelerating your path to market. Whether you need a US Agent, support with a 510(k) or PMA submission, or a comprehensive global regulatory strategy, Pure Global is your partner. Learn more about our services at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

FDA 510(k) Exemption for Unclassified Devices: New June 2026 Guidance

The US FDA has released a new final guidance, effective June 4, 2026, exempting certain unclassified medical devices from 510(k) premarket notification. This episode explains what 'unclassified devices' are, how this policy streamlines their market access pathway, and the specific actions manufacturers should take to leverage this change while remaining compliant with FDA's General Controls. Key Questions: - What are 'unclassified' medical devices under FDA regulations? - Which specific device types are now exempt from 510(k) submission as of June 2026? - How does this new guidance impact the market entry strategy for these products? - What are 'General Controls' and why do they still apply to 510(k)-exempt devices? - Does this exemption mean manufacturers no longer need a quality management system? - What are the immediate, practical steps regulatory affairs teams should take in response to this guidance? - How can this change accelerate timelines and reduce costs for product development? - Where can I find the official list of newly exempted devices? Sources: - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global helps MedTech and IVD companies accelerate global market access. Our experts can help you interpret new FDA guidance, determine the regulatory status of your devices, and develop an efficient US market entry strategy. We use advanced AI tools to compile technical dossiers and manage submissions, ensuring compliance while reducing your time to market. Whether you're a startup or a multinational enterprise, our end-to-end solutions, including local representation and post-market surveillance, provide a streamlined path for your products. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

EU AI Act & Medical Devices: Deadline Extended to 2028 for High-Risk Systems

The European Union has extended the compliance deadline for the AI Act for high-risk medical devices and IVDs already regulated by the MDR and IVDR. A provisional agreement on the Digital Omnibus package has postponed the application date by two years to August 2, 2028. This episode explores what this delay means for manufacturers, how it impacts compliance strategies, and the practical steps regulatory and quality teams should take to prepare for the eventual implementation. Key Questions: - What is the new AI Act compliance deadline for high-risk medical devices? - How does the Digital Omnibus package affect MDR and IVDR manufacturers? - Why was the original 2026 deadline for the AI Act extended? - What does this extension mean for your AI governance and QMS integration strategy? - Should you pause your AI Act compliance activities because of the delay? - How do the requirements of the AI Act and the MDR/IVDR overlap? - What practical steps should regulatory teams take over the next two years? - How will harmonized standards for AI in medical devices evolve before 2028? Sources: - https://www.medtech-europe.org/news/medtech-europe-reaction-to-the-provisional-agreement-on-the-digital-omnibus-on-ai/ - https://www.morganlewis.com/pubs/2026/05/recent-eu-and-uk-medical-devices-developments-eu-mdr-ivdr-eu-ai-act-uk-medical-devices-regime - https://www.consilium.europa.eu/en/press/press-releases/2026/05/07/artificial-intelligence-council-and-parliament-agree-to-simplify-and-streamline-rules/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 markets. Our experts help you navigate complex requirements like the EU AI Act and MDR/IVDR, ensuring your products remain compliant from initial registration through post-market surveillance. Leverage our advanced AI tools and global expertise to accelerate your market entry. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, and explore our free AI tools and database at https://pureglobal.ai.

FDA 510(k) Exemption Guidance 2026: Five New Product Codes Exempted

The US FDA issued a final guidance on June 4, 2026, immediately exempting five unclassified medical device product codes from 510(k) premarket notification requirements. This episode details the guidance, 'Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements,' explaining which manufacturers are affected, the scope of the FDA's enforcement discretion, and the critical regulatory obligations—like QMSR, registration, and listing—that remain in effect. We outline practical steps for regulatory teams to adapt their market access strategies in response to this change. Key Questions: - What is the new FDA guidance issued on June 4, 2026? - Which types of medical devices are now exempt from 510(k) notification? - Is this 510(k) exemption effective immediately? - Does this exemption mean manufacturers can ignore all FDA regulations? - What are the remaining obligations, such as QMSR and device listing? - How does this change the market access pathway for these specific devices? - What immediate steps should regulatory teams take in response to this guidance? - How can companies verify if their product code is on the new exemption list? Sources: - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intent-exempt-certain-unclassified-medical-devices-premarket-notification-requirements - https://www.federalregister.gov/documents/2026/06/05/2026-11303/intent-to-exempt-certain-unclassified-medical-devices-from-premarket-notification-requirements - https://www.raps.org/news-and-articles/news-articles/2026/6/fda-to-exempt-five-more-unclassified-devices-fr How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex regulatory landscapes and accelerate market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical submissions for authorities like the US FDA. We can help you understand the impact of new guidance, update your compliance framework, and ensure all requirements beyond 510(k) exemption, such as QMSR and registration, are met. For support with your US market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

China NMPA's New Dynamic Medical Device Classification: What Manufacturers Need to Know

This episode explores the China NMPA's new dynamic adjustment procedure for its Medical Device Classification Catalog, effective June 1, 2026. We discuss what this shift from a static to an evolving system means for manufacturers, including the impact of announcements No. 52 and No. 53, and the new obligation to continuously monitor for changes that could affect regulatory pathways, timelines, and costs for market access in China. Key Questions: - What is the NMPA's new dynamic adjustment procedure for medical device classification? - When did this new Chinese regulation take effect? - How do announcements No. 52 and No. 53 of 2026 change the classification process? - Why must manufacturers now continuously monitor the NMPA's classification catalog? - What are the risks if my device is reclassified from Class II to Class III? - How can a change in classification impact my market access strategy in China? - What practical steps can my regulatory team take to stay compliant? - How should we update our QMS to address this new requirement? Sources: - https://vcbeat.top/89484/ How Pure Global can help: Navigating dynamic regulatory landscapes like China's NMPA is critical for market success. Pure Global helps MedTech and IVD companies streamline global market access with end-to-end consulting. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets. We provide continuous regulatory monitoring to ensure your products remain compliant with evolving rules, like the new NMPA classification procedure. To secure and maintain your market presence in China and beyond, visit us at https://pureglobal.com, contact info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.